A machine learning technology developed to spot dangerous medical conditions before they worsen has shown its value in a trial.
Sanofi has refused both requests from the Government of the Philippines to refund used doses of its Dengvaxia vaccine as well as the costs of medical treatment of first-time dengue patients who were harmed after its use in the nation’s vaccination programme of 837,000 children.
A second patient has been treated in a historic gene editing study in California, and no major side effects or safety issues have emerged from the first man’s treatment nearly three months ago, doctors revealed Tuesday.
Bristol-Myers Squibb has revealed promising data from its ongoing Phase 3 study investigating the efficacy of Opdivo (nivolumab) in combination with Yervoy (ipilimumab) compared to chemotherapy in the first-line treatment of advanced non-small-cell lung cancer (NSCLC) in patients whose cancers have a high tumour mutation burden (TMB), regardless of PD-L1 expression.
With the global increase of lung diseases such as asthma, severe bronchitis and emphysema, lung function tests are becoming a bigger concern for many people.
Pharma giant AstraZeneca has seen a fourfold increase in research productivity following a narrowing of disease focus and cuts in laboratory and staff over the past seven years, Reutersreported Thursday.
FDA is warning that the liver disease medicine Ocaliva (obeticholic acid) has been incorrectly dosed daily instead of weekly in patients with moderate to severe primary biliary cholangitis (PBC), a rare chronic liver disease, increasing the risk of serious liver injury. To ensure correct dosing and reduce the risk of liver problems, FDA is clarifying the current recommendations for screening, dosing, monitoring, and managing PBC patients with moderate to severe liver disease taking Ocaliva. FDA is adding a new Boxed Warning, FDA’s most prominent warning, to highlight this information in the prescribing information of the drug label. FDA is also requiring a Medication Guide for patients to inform them about this issue.
HAIFA, Israel and MIAMI, Florida – INSIGHTEC®, a commercial-stage medical technology company revolutionizing surgery with incisionless MRI-guided focused ultrasound (MRgFUS) announced today the closing of a $150 million Series E private equity investment round. Koch Disruptive Technologies (KDT), a subsidiary of Koch Industries, focused on finding and funding innovative and emerging companies, led the round with a $100 million investment.
Researchers say the approach breaks new ground in treating cancer non-invasively and with unprecedented precision.
The nicotine in e-cigarettes seems to damage DNA in ways that may increase cancer risk, a new study in mice suggests.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.